A revolutionary cancer treatment could transform autoimmune disease

An immunotherapy originally developed for cancer is now poised to revolutionize autoimmune disease treatment, with early trials showing 60% of lupus patients achieving remission. The treatment, which engineers patients’ own T-cells to target rogue immune cells, has already cured 90% of blood cancer patients in phase 3 trials. When compared to the average autoimmune drug, priced at $50,000 annually, this one-time infusion could slash lifetime costs by 80% while offering superior efficacy.